Updated: Dec 8, 2021
Ultrasound AI software company recognized for their innovation and achievements in the Digital Health category
NEW YORK, December 8, 2021 -- CB Insights today named DiA Imaging Analysis to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.
DiA Imaging Analysis is the world’s leading provider of advanced AI-based solutions for ultrasound analysis, making the use and analysis of ultrasound images smarter, faster, and more accessible. With a focus on the cardiac and abdominal space, DiA’s LVivo Toolbox uses advanced pattern recognition, deep learning and machine learning algorithms to automatically imitate the way the human eye detects image borders and identifies motion, providing fast and accurate analysis to support ultrasound users of all levels of experience. The company’s cross-platform and vendor- neutral solution allows for easy integration onto any existing ultrasound device or healthcare IT/PACS system as a part of their pre existing workflow.
“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year's class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”
“We’re extremely proud to be selected from over 11,000 medtech companies as one of the CB Insight’s most promising private digital health companies,” said Hila Goldman-Aslan, CEO of DiA Imaging Analysis. “This is yet another acknowledgment of DiA's efforts automating the way clinicians analyze ultrasound images at point-of-care and in the Echo Lab. DiA is continuously expanding its product lines to support additional clinical applications, and we look forward to introducing our upcoming new offerings in 2022.”
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.
DiA Imaging Analysis offers seven FDA cleared products and partnerships with 11 leading channels, such as GE Healthcare, Philips, and IBM Watson. With 3,000 end users and availability in over 20 countries, DiA has recently secured $14 million in additional investments, resulting in a total of $25 million in funding, enabling the company to expand their portfolio of FDA/CE Marked solutions.
About CB Insights
CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
CB Insights Press Contact:
About DiA Imaging Analysis
DiA Imaging Analysis is a leading provider of FDA cleared and CE marked ultrasound AI software solutions that make the use and analysis of ultrasound images smarter, faster, and accessible to all. The company's LVivo product line for cardiac and abdominal automated analysis allows clinicians with various levels of ultrasound experience to use and analyze ultrasound images on their ultrasound devices or healthcare IT systems with increased speed, efficiency and accuracy. DiA serves thousands of end-users worldwide. For additional information, please visit http://www.dia-analysis.com.
DiA Imaging Analysis